{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T04:02:21Z","timestamp":1748145741893,"version":"3.41.0"},"reference-count":24,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,5,20]]},"DOI":"10.1248\/bpb.b25-00027","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T22:07:34Z","timestamp":1747692454000},"page":"650-656","source":"Crossref","is-referenced-by-count":0,"title":["External Validation of Population Pharmacokinetic Models for Unbound Cefazolin in Patients Receiving Prophylactic Dosing"],"prefix":"10.1248","volume":"48","author":[{"given":"Toshiaki","family":"Komatsu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kitasato University Hospital, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Kawai","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Infectious Diseases, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Akamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Hospital, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Hospital, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyasu","family":"Tsumura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Urology, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Iwamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"},{"name":"Department of Urology, Tomei Atsugi Hospital, 232 Funako, Atsugi, Kanagawa 243\u20138571, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Anesthesiology, Kitasato University School of Medicine, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Hanaki","sequence":"additional","affiliation":[{"name":"Infection Control Research Center, \u014cmura Satoshi Memorial Institute, Kitasato University, 5\u20139\u20131 Shirokane, Minato-ku, Tokyo 108\u20138641, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 1\u201315\u20131 Kitazato, Minami-ku, Sagamihara 252\u20130375, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am. J. Health Syst. Pharm.<\/i>, <b>70<\/b>, 195\u2013283 (2013).","DOI":"10.2146\/ajhp120568"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Peppard WJ, Eberle DG, Kugler NW, Mabrey DM, Weigelt JA. Association between pre-operative cefazolin dose and surgical site infection in obese patients. <i>Surg. Infect.<\/i> (Larchmt.), <b>18<\/b>, 485\u2013490 (2017).","DOI":"10.1089\/sur.2016.182"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant <i>Staphylococcus aureus<\/i>. <i>Infect. Control Hosp. Epidemiol.<\/i>, <b>28<\/b>, 1047\u20131053 (2007).","DOI":"10.1086\/520731"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Shi C, Xiao Y, Zhang Q, Li Q, Wang F, Wu J, Lin N. Efficacy and safety of cefazolin <i>versus<\/i> antistaphylococcal penicillins for the treatment of methicillin-susceptible <i>Staphylococcus aureus<\/i> bacteremia: a systematic review and meta-analysis. <i>BMC Infect. Dis.<\/i>, <b>18<\/b>, 508 (2018).","DOI":"10.1186\/s12879-018-3418-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Boonchan T, Wilasrusmee C, McEvoy M, Attia J, Thakkinstian A. Network meta-analysis of antibiotic prophylaxis for prevention of surgical-site infection after groin hernia surgery. <i>Br. J. Surg.<\/i>, <b>104<\/b>, e106\u2013e117 (2017).","DOI":"10.1002\/bjs.10441"},{"key":"6","unstructured":"6) Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. <i>Surgery<\/i>, <b>50<\/b>, 161\u2013168 (1961)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. <i>Am. J. Surg.<\/i>, <b>189<\/b>, 395\u2013404 (2005).","DOI":"10.1016\/j.amjsurg.2005.01.015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Zelenitsky SA, Lawson C, Calic D, Ariano RE, Roberts JA, Lipman J, Zhanel GG. Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. <i>J. Antimicrob. Chemother.<\/i>, <b>71<\/b>, 2902\u20132908 (2016).","DOI":"10.1093\/jac\/dkw247"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) So W, Kuti JL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and tissue for patients with complicated skin and soft tissue infections (cSSTI). <i>Infect. Dis. Ther.<\/i>, <b>3<\/b>, 269\u2013279 (2014).","DOI":"10.1007\/s40121-014-0049-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Komatsu T, Natsume Y, Uchiyama K, Ikeda S, Tomoda Y, Takayama Y, Takaso M, Hanaki H, Atsuda K. Population pharmacokinetic and pharmacodynamic target attainment analysis of cefazolin in the serum and hip joint capsule of patients undergoing total hip arthroplasty. <i>Antimicrob. Agents Chemother<\/i>, <b>65<\/b>, e02114\u201320 (2021).","DOI":"10.1128\/AAC.02114-20"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Komatsu T, Kawai Y, Takayama Y, Akamada Y, Kusume E, Ikeda M, Tsumura H, Ishii D, Iwamura M, Okamoto H, Hanaki H, Otori K. Population pharmacokinetics and pharmacodynamic target attainment analysis of cefazolin using total and unbound serum concentration in patients with prostatectomy or nephrectomy. <i>Antimicrob. Agents Chemother.<\/i>, <b>68<\/b>, e0026724 (2024).","DOI":"10.1128\/aac.00267-24"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. <i>J. Pharmacokinet. Biopharm.<\/i>, <b>9<\/b>, 503\u2013512 (1981).","DOI":"10.1007\/BF01060893"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chung EK, Cheatham SC, Healy DP, Stock AH, Utley S, Campion M, Murrey T, Gesenhues AM, Jeffery J, Kays MB. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight. <i>Int. J. Antimicrob. Agents.<\/i>, <b>61<\/b>, 106751 (2023).","DOI":"10.1016\/j.ijantimicag.2023.106751"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Asada M, Nagata M, Mizuno T, Uchida T, Takahashi H, Makita K, Arai H, Kijima S, Echizen H, Yasuhara M. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>77<\/b>, 735\u2013745 (2021).","DOI":"10.1007\/s00228-020-03045-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kim KM, Jung J, Lee JM, Yang HS, Bang JY, Lee EK, Choi BM, Noh GJ. The expected advantage of administering prophylactic antibiotics using target-concentration controlled infusion: development of a new pharmacokinetic model of cefazolin. <i>Clin. Exp. Pharmacol. Physiol.<\/i>, <b>49<\/b>, 731\u2013739 (2022).","DOI":"10.1111\/1440-1681.13648"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bausch S, Dr\u00e4ger S, Charitos-Fragkakis P, Egli A, Moser S, Hinic V, Kuehl R, Bassetti S, Siegemund M, Rentsch KM, Hermann L, Sch\u00f6ning V, Hammann F, Sendi P, Osthoff M. Target attainment and population pharmacokinetics of cefazolin in patients with invasive <i>Staphylococcus aureus<\/i> infections: a prospective cohort study. <i>Antibiotics<\/i> (Basel), <b>13<\/b>, 928 (2024).","DOI":"10.3390\/antibiotics13100928"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Brill MJE, Houwink API, Schmidt S, Van Dongen EPA, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CAJ. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese <i>versus<\/i> non-obese patients determined using clinical microdialysis. <i>J. Antimicrob. Chemother.<\/i>, <b>69<\/b>, 715\u2013723 (2014).","DOI":"10.1093\/jac\/dkt444"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ryan RL, Jackson D, Hopkins G, Eley V, Christensen R, Van Zundert AAJ, Wallis SC, Lipman J, Parker SL, Roberts JA. Plasma and interstitial fluid pharmacokinetics of prophylactic cefazolin in elective bariatric surgery patients. <i>Antimicrob. Agents Chemother.<\/i>, <b>66<\/b>, e0041922 (2022).","DOI":"10.1128\/aac.00419-22"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Alli A, Paruk F, Roger C, Lipman J, Calleemalay D, Wallis SC, Scribante J, Richards GA, Roberts JA. Peri-operative pharmacokinetics of cefazolin prophylaxis during valve replacement surgery. <i>PLOS ONE<\/i>, <b>18<\/b>, e0291425 (2023).","DOI":"10.1371\/journal.pone.0291425"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) de Velde F, Mouton JW, de Winter BCM, van Gelder T, Koch BCP. Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives. <i>Pharmacol. Res.<\/i>, <b>134<\/b>, 280\u2013288 (2018).","DOI":"10.1016\/j.phrs.2018.07.005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Schmidt S, R\u00f6ck K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, Derendorf H. Effect of protein binding on the pharmacological activity of highly bound antibiotics. <i>Antimicrob. Agents Chemother.<\/i>, <b>52<\/b>, 3994\u20134000 (2008).","DOI":"10.1128\/AAC.00427-08"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kirby WM, Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. <i>J. Infect. Dis.<\/i>, <b>128<\/b><b>(Suppl. 2)<\/b>, S341\u2013S346 (1973).","DOI":"10.1093\/infdis\/128.Supplement_2.S341"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lanoisel\u00e9e J, Chaux R, Hodin S, Bourayou S, Gibert A, Philippot R, Molliex S, Zufferey PJ, Delavenne X, Ollier E. Population pharmacokinetic model of cefazolin in total hip arthroplasty. <i>Sci. Rep.<\/i>, <b>11<\/b>, 19763 (2021).","DOI":"10.1038\/s41598-021-99162-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Roberts JA, Udy AA, Jarrett P, Wallis SC, Hope WW, Sharma R, Kirkpatrick CMJ, Kruger PS, Roberts MS, Lipman J. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>J. Antimicrob. Chemother.<\/i>, <b>70<\/b>, 1495\u20131502 (2015).","DOI":"10.1093\/jac\/dku564"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b25-00027\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:09:10Z","timestamp":1748059750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b25-00027\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00027","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"b25-00027"}}